Infliximab, a monoclonal antibody to TNF-alpha, which neutralizes TNF-alpha and down-regulates the expression of granulocyte-macrophage colony-stimulating factor has been demonstrated to be an effective therapy for Crohn's disease, rheumatoid arthritis and other Th1-mediated disorders[9]. The gene discussed is TNF; the disease is Crohn disease.